



Kura Oncology Announces Upcoming Presentations at American Society of Hematology Annual Meeting

November 1, 2017

SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that four abstracts relating to the Company's lead product candidate, tipifarnib, have been accepted for presentation at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held from December 9-12, 2017 in Atlanta. The following abstracts were published today and are now available on the ASH website at www.hematology.org.

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib in Acute Myeloid Leukemia and Myelodysplastic Syndromes (Abstract #3957)

Session Name: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster III

Date: Monday, December 11, 2017

Presentation Time: 6:00 PM - 8:00 PM

Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2

The CXCL12/CXCR4 Pathway As a Potential Target of Tipifarnib: Preliminary Results from an Open-Label, Phase II Study in Relapsed or Refractory Peripheral T-Cell Lymphoma (Abstract #2788)

Session Name: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster II

Date: Sunday, December 10, 2017

Presentation Time: 6:00 PM - 8:00 PM

Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2

Preliminary Results from an Open-Label, Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML) (Abstract #2963)

Session Name: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II

Date: Sunday, December 10, 2017

Presentation Time: 6:00 PM - 8:00 PM

Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2

Killer Immunoglobulin-like Receptors (KIR) in Low-Risk Myelodysplastic Syndrome: Genotyping and Gene Expression Evaluation (Abstract #1677)

Session Name: 636. Myelodysplastic Syndromes—Basic and Translational Studies: Poster I

Date: Saturday, December 9, 2017

Presentation Time: 5:30 PM - 7:30 PM

Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology's lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura's pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company's website at www.kuraoncology.com.

Forward-Looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of tipifarnib, progress and expected timing of Kura Oncology's drug development programs and clinical trials and plans regarding future clinical trials and development activities. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura Oncology may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "promise," "potential," "expects," "plans," "anticipates," "intends," "continues," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura Oncology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:

Pete De Spain
Vice President, Investor Relations &
Corporate Communications
Kura Oncology, Inc.
(858) 500-8803
pete@kuraoncology.com

Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
robert.uhl@westwicke.com

Mark Corbae
Vice President
Canale Communications
(619) 849-5375
mark@canalecomm.com

Source: Kura Oncology, Inc.